Pfizer Corporation

Nuvalent, Inc.

Scot Richard Mente

Jennifer Elizabeth Davoren

Ivan Viktorovich Efremov

Amy Beth Dounay

David Lawrence Firman Gray

Bruce Nelsen Rogers

Lei Zhang

Steven Victor O'Neil

Chewah Lee

Michael Aaron Brodney

Michael Eric Green

Jaclyn Louise Henderson

Chakrapani Subramanyam

Peter M Jones

Mark E Schnute

Li Huang Xing

Neelu Kaila

Matthew D Shair

Liying Zhang

John David Trzupek

Henry Efrem Pelish

Andrew Christopher Flick

Michael L Vazquez

Joshua Courtney Horan

Edouard Zamaratski

Anupong Tangpeerachaikul

Rayomand Jal Unwalla

Xinxing Tang

Goran Mattias Wennerstal

Mark Edward Schnute

David Lawrence Gray

Steven Victor O'neil

Patrick Robert Verhoest

Jotham Wadsworth Coe

Christopher John Helal

Atli Thorarensen

Travis T Wager

Christoph Wolfgang Zapf

James Robert Blinn

Justin Ian Montgomery

Todd William Butler

Marvin Jay Meyers

Baudouin Gerard

Ravi G Kurumbail

Ramalakshmi Yegna Chandrasekaran

Gregory Wayne Kauffman

Chris John Helal

Kapildev Kashmirilal Arora

Natasha Mariam Kablaoui

Danica Antonia Rankic

Matthew Francis Dunn

Göran Mattias Wennerstål

John Arthur Allen

Edward Raymond Guilmette

Anthony Richard Harris

Deane Milford Nason

Wenjian Xu

Kristin Lynne Andrews

Yuting Sun

Ivan V Efremov

David L F Gray

Jennifer E Davoren

Göran Mattias WENNERSTÅL

Deane Milford Ii Nason

Steven V O'NEIL

Todd W Butler

Steven V O'neil

James Richard Kiefer

Bruce N Rogers

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.

Heteroaromatic macrocyclic ether chemotherapeutic agents

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.

Disclosed are amino-substituted heteroaromatic compounds such as a compound of Formula (I): pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.

Amino-substituted heteroaryls for treating cancers with EGFR mutations

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

Heteroaromatic compounds and their use as dopamine D1 ligands

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR&#x3b3; activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof

The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.

Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof

The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR&#x3b3; activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (&#x3ba;-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.

Heteroarylphenoxy benzamide kappa opioid ligands

Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof

Growing community of inventors

Arlington, MA, United States of America

Scot Richard Mente